Oct 23, 2026
CD Bioparticles launches High-Loading EGCG Nanoparticles Development services to support combination antitumor therapy and efficient drug delivery.
New York, NY, United States, October 23, 2026 /MarketersMEDIA/ -- CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, has announced the launch of its High-Loading EGCG Nanoparticles Development services to support researchers and biotechnology professionals in advancing combination antitumor therapy and efficient drug delivery. This drug-loading nanoparticle platform is based on Epigallocatechin-3-gallate (EGCG), and can help address key challenges associated with active ingredient loading, formulation stability, and delivery system optimization.
Natural products have great potential in biomedical research, drug development and clinical applications as they can be used medicinal sources to treat cancer, bacterial and fungal infections, inflammation and other diseases. These compounds in particular exhibit excellent biocompatibility, broad-spectrum biological activity and highly targeted effects, making them potent anti-cancer chemopreventive and chemotherapeutic agents with minimal side effects. Furthermore, these abundant and diverse natural sources can help to reduce the cost of cancer treatment.
EGCG is a natural phenolic compound found in foods and beverages (particularly tea) that exhibits a wide range of biological activities, including antioxidant, antibacterial, anti-obesity, anti-inflammatory and anticancer properties. The formation of EGCG self-assembled nanoparticles (ENPs) during the oxidation process is driven by intermolecular interactions, which maintain the stability of the nanoparticles. EGCG-based nanoparticles are an excellent carrier platform for antitumour drug delivery. To support researchers' work, CD Bioparticles now offers a high-loading EGCG-based nanoparticle platform designed specifically for combined antitumour therapy and efficient drug delivery.
CD Bioparticles offers custom, high-loading EGCG nanoparticle services to leverage advanced nanomedicine delivery technologies to achieve high loading, controlled release and targeted delivery, thereby maximizing the therapeutic potential of EGCG. The platform achieves loading rates of 30–50% (compared to 5–10% for traditional carriers), thereby increasing the effective dose while reducing the required carrier amount.
Additionally, the platform offers broad drug compatibility and is capable of simultaneously loading both hydrophilic and hydrophobic drugs, providing an efficient platform for multi-drug combination therapy. CD Bioparticles supports anti-tumour combination therapy regimens to achieve drug synergy and improve treatment outcomes. With a particle size range of 100–200 nm, CD Bioparticles' nanoparticles enhance tumour permeability and cellular uptake.
CD Bioparticles' comprehensive services include nanoparticle preparation customization, drug loading and capacity optimization, precise particle size and morphology characterization, stability and release performance evaluation, biocompatibility and efficacy assessment, and scalable production. These services can support researchers in various applications, such as in vitro drug screening and delivery mechanism studies, antitumour combination drug delivery, and targeted drug delivery and nanomedicine development.
Researchers and pharmaceutical developers working in oncology, targeted nanomedicine and sustained-release systems R&D who would like to learn more about CD Bioparticles' High-Loading-Capacity EGCG Nanoparticle Development services, or who would like to discuss custom project requirements and explore available development solutions, please visit https://www.cd-bioparticles.net/services/custom-high-loading-egcg-nanoparticles-development-service.html.
About CD Bioparticles
CD Bioparticles is an established drug delivery company that provides customized solutions for developing and manufacturing novel biocompatible drug delivery systems. It specializes in various formulation and drug delivery technologies, from conventional liposomes and PEGylated liposomes to polymer microspheres and nanoparticles for drug delivery. The company also provides contract research services for drug delivery formulation, formulation feasibility study, process development and scale-up, as well as analytical and non-clinical research services.
Contact Info:
Name: Richard J. Gray
Email: Send Email
Organization: CD Bioparticles
Website: https://www.cd-bioparticles.net/
Release ID: 89207091
In case of detection of errors, concerns, or irregularities in the content provided in this press release, or if there is a need for a press release takedown, we strongly encourage you to reach out promptly by contacting [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our efficient team will be at your disposal for immediate assistance within 8 hours – resolving identified issues diligently or guiding you through the removal process. We take great pride in delivering reliable and precise information to our valued readers.
"We reversed out of there as quickly as we could, screaming and certain that we just stumbled upon something we shouldn’t have." View Entire Post ›
Leading online travel agent, Opodo - part of eDreams ODIGEO - investigates how social media shapes the way we travel, sharing insights from its latest global poll of 9,000 respondents, including 2,000 from the UK. The data includes what influences us, what we post, how often we use social media while on holiday, and more. Opodo also compares its findings to a similar global poll it conducted in 2024 (poll of 9,000 people, including 2,000 from the UK) to explore how attitudes have evolved.
UK interest in skiing in Japan has never been higher. Ski Safari’s Japan passenger numbers grew by 32% year on year in winter 2025/26, and are on track to grow by a further 17% for winter 2026/27, while 2026 has also seen record numbers of UK Google searches for skiing in Japan. In response, Ski Safari is expanding its popular Japan programme, adding Madarao, Naeba and Shiga Kogen for winter 2026/27.
As rail travel continues to enjoy a global resurgence, Peru is emerging as one of the world’s most spectacular destinations to experience it. From the soaring Andes and the Sacred Valley to the shores of Lake Titicaca, the country’s most iconic rail routes transform the journey itself into a highlight, pairing dramatic scenery with exceptional dining, cultural experiences and warm Peruvian hospitality. Whether travelling to Machupicchu, crossing the Altiplano or exploring southern Peru in luxury, travellers can discover the country’s landscapes, heritage and renowned gastronomy from the comfort of panoramic carriages.
FHS Africa will now take place on 28–29 April 2027 at Speke Resort Munyonyo, Kampala, Uganda, aligning with the Pearl of Africa Tourism Expo (POATE) to create greater synergies between hospitality investment, tourism promotion and business development across the region. The summit was originally scheduled for 2–3 February 2027. The revised dates reflect a positive strategic decision to strengthen collaboration between two important platforms for Uganda’s tourism and hospitality sectors. By aligning FHS Africa with POATE, the summit will create new opportunities to connect the international hospitality investment community with Uganda’s tourism industry, while showcasing the country’s potential as a destination for business, investment and leisure.
The Anguilla Tourist Board (ATB) strengthened its engagement with the United Kingdom’s luxury travel market at Virtuoso On Tour London 2026, where Deputy Director of Tourism Chantelle Richardson delivered a destination presentation to 200 travel professionals during the event’s lunch program. Virtuoso On Tour London, held Oct. 20-21, brought together Virtuoso travel advisors and preferred partners to exchange industry insights, explore evolving luxury travel preferences and build business relationships. For Anguilla, it provided an opportunity to deepen established partnerships, develop new trade connections and increase destination awareness among advisors serving discerning travelers.
“Many people, when they first smell Chinese incense, describe it as smelling like Chinese medicine,” says Shanghai-based incense master Sun Na. “And it’s true, the classic Chinese incense we’re talking about is primarily medicinal in character.” She points to a spherical censer, a vessel designed to burn incense. “In winter, you could put it under the blankets to scent and warm the bedding,” she says. “If you had trouble sleeping, calming herbs could be added. This is what we call zhi wei bing –...
“GET THIS!! I tried this on and immediately ordered another color.” View Entire Post ›
The queue outside Bar Leone isn’t just for its acclaimed cocktails. More than a few guests are making a pilgrimage for Leone’s signature smoked olives – cheekily called “the world’s best olives (maybe)” – and its mortadella sandwich, with layers of thinly sliced mortadella, creamy whipped ricotta and tangy pickled chillies sandwiched between crispy focaccia. Up the road at sister bar Montana, the pulled-pork sliders have their own following. Not long ago, bar food in Hong Kong usually meant a...
And you're thinking about a million different things besides the personal item for the plane. View Entire Post ›
Come here, fellow walking messes. It's time to invest in a slim wallet tracker and some shoe bags for your dirty sneaks. View Entire Post ›
These silicone bottle covers and these clear waterproof shoe bags are things you get yourself now so you can thank yourself later. View Entire Post ›
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.